Evaluation of efficacy and tolerability of first-line therapies in NMOSD

OBJECTIVETo compare the efficacy and the risk of severe infectious events of immunosuppressive agents used early as first-line therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). METHODSWe retrospectively included patients with NMOSD and a seropositive status for aquaporin 4 or...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neurology 2020-04, Vol.94 (15), p.e1645-e1656
Hauptverfasser:	Poupart, Julien, Giovannelli, Jonathan, Deschamps, Romain, Audoin, Bertrand, Ciron, Jonathan, Maillart, Elisabeth, Papeix, Caroline, Collongues, Nicolas, Bourre, Bertrand, Cohen, Mickael, Wiertlewski, Sandrine, Outteryck, Olivier, Laplaud, David, Vukusic, Sandra, Marignier, Romain, Zephir, Hélène
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies - therapeutic use Aquaporin 4 - drug effects Aquaporin 4 - immunology Azathioprine - adverse effects Azathioprine - therapeutic use Female Humans Immunosuppressive Agents - therapeutic use Life Sciences Male Middle Aged Mycophenolic Acid - administration & dosage Mycophenolic Acid - therapeutic use Neuromyelitis Optica - drug therapy Neuromyelitis Optica - immunology Neurons and Cognition Recurrence Rituximab - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!